Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121264 · ClinicalTrials.gov registry record · Phase 1
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00121264: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00121264 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121264, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of 17-AAG when given together with sorafenib in treating patients with unresectable or metastatic solid tumors. Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving 17-AAG together with sorafenib may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG tanespimycin
- PROCEDURE magnetic resonance imaging
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121264
The ClinicalTrials.gov registry entry for NCT00121264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00121264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121264 about?
NCT00121264 is a clinical study titled "17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors". This phase I trial is studying the side effects and best dose of 17-AAG when given together with sorafenib in treating patients with unresectable or metastatic solid tumors. Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the ce...
What is the current status of trial NCT00121264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2005-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00121264?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), tanespimycin (DRUG), magnetic resonance imaging (PROCEDURE), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00121264?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.